Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.

Perera TPS, Jovcheva E, Mevellec L, Vialard J, De Lange D, Verhulst T, Paulussen C, Van De Ven K, King P, Freyne E, Rees DC, Squires M, Saxty G, Page M, Murray CW, Gilissen R, Ward G, Thompson NT, Newell DR, Cheng N, Xie L, Yang J, Platero SJ, Karkera JD, Moy C, Angibaud P, Laquerre S, Lorenzi MV.

Mol Cancer Ther. 2017 Jun;16(6):1010-1020. doi: 10.1158/1535-7163.MCT-16-0589. Epub 2017 Mar 24.

2.

Iron-Catalyzed Synthesis of Sulfur-Containing Heterocycles.

Bosset C, Lefebvre G, Angibaud P, Stansfield I, Meerpoel L, Berthelot D, Guérinot A, Cossy J.

J Org Chem. 2017 Apr 21;82(8):4020-4036. doi: 10.1021/acs.joc.6b01827. Epub 2016 Oct 13.

PMID:
27736056
3.

Access to Silylated Pyrazole Derivatives by Palladium-Catalyzed C-H Activation of a TMS group.

Mistico L, Querolle O, Meerpoel L, Angibaud P, Durandetti M, Maddaluno J.

Chemistry. 2016 Jul 4;22(28):9687-92. doi: 10.1002/chem.201601533. Epub 2016 Jun 7.

PMID:
27271020
4.

Tankyrase inhibition impairs directional migration and invasion of lung cancer cells by affecting microtubule dynamics and polarity signals.

Lupo B, Vialard J, Sassi F, Angibaud P, Puliafito A, Pupo E, Lanzetti L, Comoglio PM, Bertotti A, Trusolino L.

BMC Biol. 2016 Jan 19;14:5. doi: 10.1186/s12915-016-0226-9.

5.

Iron-Catalyzed Synthesis of C2 Aryl- and N-Heteroaryl-Substituted Tetrahydropyrans.

Bosset C, Angibaud P, Stanfield I, Meerpoel L, Berthelot D, Guérinot A, Cossy J.

J Org Chem. 2015 Dec 18;80(24):12509-25. doi: 10.1021/acs.joc.5b02371. Epub 2015 Nov 25.

PMID:
26554431
6.

Anionic access to silylated and germylated binuclear heterocycles.

Boddaert T, François C, Mistico L, Querolle O, Meerpoel L, Angibaud P, Durandetti M, Maddaluno J.

Chemistry. 2014 Aug 4;20(32):10131-9. doi: 10.1002/chem.201402597. Epub 2014 Jul 3.

PMID:
24995989
7.

Synthesis of substituted indenones and indanones by a Suzuki-Miyaura coupling/acid-promoted cyclisation sequence.

Butkevich AN, Ranieri B, Meerpoel L, Stansfield I, Angibaud P, Corbu A, Cossy J.

Org Biomol Chem. 2014 Feb 7;12(5):728-31. doi: 10.1039/c3ob41974f. Epub 2013 Dec 10.

PMID:
24323234
8.

Cobalt-catalyzed diastereoselective synthesis of C-furanosides. Total synthesis of (-)-isoaltholactone.

Nicolas L, Izquierdo E, Angibaud P, Stansfield I, Meerpoel L, Reymond S, Cossy J.

J Org Chem. 2013 Dec 6;78(23):11807-14. doi: 10.1021/jo401845q. Epub 2013 Nov 12.

PMID:
24127819
9.

Tandem Suzuki-Miyaura coupling/acid-catalyzed cyclization between vinyl ether boronates and vinyl halides: a concise approach to polysubstituted furans.

Butkevich AN, Meerpoel L, Stansfield I, Angibaud P, Corbu A, Cossy J.

Org Lett. 2013 Aug 2;15(15):3840-3. doi: 10.1021/ol4014574. Epub 2013 Jul 15.

PMID:
23855589
10.

Diastereoselective metal-catalyzed synthesis of C-aryl and C-vinyl glycosides.

Nicolas L, Angibaud P, Stansfield I, Bonnet P, Meerpoel L, Reymond S, Cossy J.

Angew Chem Int Ed Engl. 2012 Oct 29;51(44):11101-4. doi: 10.1002/anie.201204786. Epub 2012 Sep 28.

PMID:
23023954
11.

Two-step one-pot synthesis of benzoannulated spiroacetals by Suzuki-Miyaura coupling/acid-catalyzed spiroacetalization.

Butkevich AN, Corbu A, Meerpoel L, Stansfield I, Angibaud P, Bonnet P, Cossy J.

Org Lett. 2012 Oct 5;14(19):4998-5001. doi: 10.1021/ol302088w. Epub 2012 Sep 21.

PMID:
22998767
12.

Intramolecular sila-Matteson rearrangement: a general access to silylated heterocycles.

François C, Boddaert T, Durandetti M, Querolle O, Van Hijfte L, Meerpoel L, Angibaud P, Maddaluno J.

Org Lett. 2012 Apr 20;14(8):2074-7. doi: 10.1021/ol300598s. Epub 2012 Apr 5.

PMID:
22480200
13.

Potent, selective inhibitors of fibroblast growth factor receptor define fibroblast growth factor dependence in preclinical cancer models.

Squires M, Ward G, Saxty G, Berdini V, Cleasby A, King P, Angibaud P, Perera T, Fazal L, Ross D, Jones CG, Madin A, Benning RK, Vickerstaffe E, O'Brien A, Frederickson M, Reader M, Hamlett C, Batey MA, Rich S, Carr M, Miller D, Feltell R, Thiru A, Bethell S, Devine LA, Graham BL, Pike A, Cosme J, Lewis EJ, Freyne E, Lyons J, Irving J, Murray C, Newell DR, Thompson NT.

Mol Cancer Ther. 2011 Sep;10(9):1542-52. doi: 10.1158/1535-7163.MCT-11-0426. Epub 2011 Jul 15.

14.

Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.

Angibaud P, Van Emelen K, Decrane L, van Brandt S, Ten Holte P, Pilatte I, Roux B, Poncelet V, Speybrouck D, Queguiner L, Gaurrand S, Mariën A, Floren W, Janssen L, Verdonck M, van Dun J, van Gompel J, Gilissen R, Mackie C, Du Jardin M, Peeters J, Noppe M, Van Hijfte L, Freyne E, Page M, Janicot M, Arts J.

Bioorg Med Chem Lett. 2010 Jan 1;20(1):294-8. doi: 10.1016/j.bmcl.2009.10.118. Epub 2009 Oct 30.

PMID:
19906529
15.

JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity.

Arts J, King P, Mariën A, Floren W, Beliën A, Janssen L, Pilatte I, Roux B, Decrane L, Gilissen R, Hickson I, Vreys V, Cox E, Bol K, Talloen W, Goris I, Andries L, Du Jardin M, Janicot M, Page M, van Emelen K, Angibaud P.

Clin Cancer Res. 2009 Nov 15;15(22):6841-51. doi: 10.1158/1078-0432.CCR-09-0547. Epub 2009 Oct 27.

16.

R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies.

Arts J, Angibaud P, Mariën A, Floren W, Janssens B, King P, van Dun J, Janssen L, Geerts T, Tuman RW, Johnson DL, Andries L, Jung M, Janicot M, van Emelen K.

Br J Cancer. 2007 Nov 19;97(10):1344-53. Epub 2007 Nov 13.

17.

Impact on farnesyltransferase inhibition of 4-chlorophenyl moiety replacement in the Zarnestra series.

Angibaud P, Mevellec L, Meyer C, Bourdrez X, Lezouret P, Pilatte I, Poncelet V, Roux B, Merillon S, End DW, Van Dun J, Wouters W, Venet M.

Eur J Med Chem. 2007 May;42(5):702-14. Epub 2007 Jan 9.

PMID:
17316920
18.

Discovery of pyrimidyl-5-hydroxamic acids as new potent histone deacetylase inhibitors.

Angibaud P, Arts J, Van Emelen K, Poncelet V, Pilatte I, Roux B, Van Brandt S, Verdonck M, De Winter H, Ten Holte P, Marien A, Floren W, Janssens B, Van Dun J, Aerts A, Van Gompel J, Gaurrand S, Queguiner L, Argoullon JM, Van Hijfte L, Freyne E, Janicot M.

Eur J Med Chem. 2005 Jun;40(6):597-606. Epub 2005 Mar 3.

PMID:
15922843
19.

Substituted azoloquinolines and -quinazolines as new potent farnesyl protein transferase inhibitors.

Angibaud P, Bourdrez X, End DW, Freyne E, Janicot M, Lezouret P, Ligny Y, Mannens G, Damsch S, Mevellec L, Meyer C, Muller P, Pilatte I, Poncelet V, Roux B, Smets G, Van Dun J, Van Remoortere P, Venet M, Wouters W.

Bioorg Med Chem Lett. 2003 Dec 15;13(24):4365-9.

PMID:
14643327
20.

4-methyl-1,2,4-triazol-3-yl heterocycle as an alternative to the 1-methylimidazol-5-yl moiety in the farnesyltransferase inhibitor ZARNESTRA.

Angibaud P, Saha AK, Bourdrez X, End DW, Freyne E, Lezouret P, Mannens G, Mevellec L, Meyer C, Pilatte I, Poncelet V, Roux B, Smets G, Van Dun J, Venet M, Wouters W.

Bioorg Med Chem Lett. 2003 Dec 15;13(24):4361-4.

PMID:
14643326
21.

Farnesyl protein transferase inhibitor ZARNESTRA R115777 - history of a discovery.

Venet M, End D, Angibaud P.

Curr Top Med Chem. 2003;3(10):1095-102. Review.

PMID:
12769710
22.

5-imidazolyl-quinolinones, -quinazolinones and -benzo-azepinones as farnesyltransferase inhibitors.

Angibaud P, Bourdrez X, Devine A, End DW, Freyne E, Ligny Y, Muller P, Mannens G, Pilatte I, Poncelet V, Skrzat S, Smets G, Van Dun J, Van Remoortere P, Venet M, Wouters W.

Bioorg Med Chem Lett. 2003 May 5;13(9):1543-7.

PMID:
12699751
23.

Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.

End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, Venet M, Sanz G, Poignet H, Skrzat S, Devine A, Wouters W, Bowden C.

Cancer Res. 2001 Jan 1;61(1):131-7.

Supplemental Content

Loading ...
Support Center